Cancer-Fighting virus injected directly into tumors shows promise in early trial
NCT ID NCT04725331
First seen Nov 21, 2025 · Last updated Jun 23, 2026 · Updated 25 times
Summary
This early-phase trial tested a new treatment called BT-001, a virus designed to infect and kill cancer cells, given alone or with the immunotherapy drug pembrolizumab. The study involved 31 people with advanced solid tumors like melanoma, lung cancer, or sarcoma that had spread. The goal was to see if the combination was safe and could shrink tumors, but the trial was stopped early, so we have limited information on how well it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre Léon Bérard
Lyon, 69008, France
-
Clinique Universitaire Saint-Luc
Brussels, 1200, Belgium
-
Hôpital Saint-Louis AP-HP
Paris, 75010, France
-
Institut Bergonié
Bordeaux, 33000, France
-
Institut Gustave Roussy
Villejuif, 94800, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BT-001 (a modified virus that targets tumors) and pembrolizumab (an immunotherapy drug)
What this could lead to
If successful, this approach could offer a new way to shrink tumors by combining a virus that attacks cancer cells with an immunotherapy that boosts the immune system.
What could go wrong
The trial was terminated early, so results are limited. The approach is still experimental, and side effects from the virus or immune reactions could be serious.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.